Medtronic PLC $MDT Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its position in Medtronic PLC (NYSE:MDT) by 20.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 260,675 shares of the medical technology company’s stock after acquiring an additional 44,215 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Medtronic were worth $25,040,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of MDT. Corundum Trust Company INC acquired a new stake in shares of Medtronic in the 3rd quarter worth approximately $27,000. Lodestone Wealth Management LLC acquired a new stake in shares of Medtronic in the 4th quarter worth approximately $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic in the 3rd quarter worth approximately $29,000. Board of the Pension Protection Fund acquired a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Medtronic in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.26% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

MDT has been the topic of a number of research reports. Citigroup lowered their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Needham & Company LLC restated a “buy” rating and issued a $120.00 price target on shares of Medtronic in a report on Thursday, March 26th. CICC Research started coverage on Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. UBS Group reaffirmed a “neutral” rating and issued a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Finally, Wells Fargo & Company started coverage on Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Medtronic Price Performance

MDT stock opened at $86.24 on Friday. Medtronic PLC has a 1 year low of $79.93 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The stock’s 50 day moving average price is $91.51 and its 200 day moving average price is $95.70. The firm has a market cap of $110.72 billion, a P/E ratio of 24.02, a PEG ratio of 2.22 and a beta of 0.75.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the company earned $1.38 EPS. Medtronic’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).